sorafenib has been researched along with epoxomicin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (epoxomicin) | Trials (epoxomicin) | Recent Studies (post-2010) (epoxomicin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 251 | 0 | 111 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harada, M; Honma, Y; Shimizu, S; Takehara, T | 1 |
1 other study(ies) available for sorafenib and epoxomicin
| Article | Year |
|---|---|
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Synergism; Humans; Leupeptins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oligopeptides; Phenylurea Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2014 |